Document is current
Any future updates will be listed below
-
Authors
Sardar, Pabitra K.
Yeung, Steven
Tow, Ruby
Luga, Jacqueline
Huang, Matthew
Shahid, Ayaz
Andresen, Bradley T.
Huang, Ying https://orcid.org/0000-0003-4756-7939
-
Funding
Funding for this research was provided by:
Division of Cancer Prevention, National Cancer Institute (R01CA269653)
- License Information
-
More Information
Article History
Received: 4 October 2024
Accepted: 1 December 2024
First Online: 6 January 2025
Declarations
:
: All data generated or analysed during this study are included in this published article.
: US Utility Patent Application (serial no. 17/676,684) was filed on 21 February 2022 for the application of R-carvedilol in cancer chemoprevention.
: Research reported in the publication was partly supported by the National Cancer Institute of the National Institutes of Health under Award Number R01CA269653. This work was also supported byWestern University of Health Sciences Intramural Student Funds as part of the Graduate Program.
: We thank Lily Kong Lim, A.S.C.P. (H.T.), at Beverly Hospital for preparing formalin-fixed paraffin-embedded tissues and H&E staining.
